Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain

Rhea-AI Summary

Helius Medical Technologies (NASDAQ:HSDT) has initiated its digital asset treasury strategy by acquiring 760,190 SOL tokens at an average cost of $231 per token. The company maintains over $335 million in cash reserves for future SOL purchases, demonstrating its commitment to the Solana ecosystem.

Solana's blockchain processes over 3,500 transactions per second and serves approximately 3.7 million daily active wallets, with more than 23 billion transactions year to date. The network offers a ~7% native staking yield. HSDT plans to continue supporting both its SOL holdings strategy and its existing neurotech and medical device operations.

Positive

• Significant initial acquisition of 760,190 SOL tokens with favorable cost basis below recent market prices
• Strong cash position of $335 million available for additional strategic purchases
• Investment in SOL offers ~7% native staking yield potential
• Company maintains dual focus on digital assets and existing medical technology operations

Negative

• Exposure to volatile cryptocurrency market prices and regulatory risks
• Significant capital allocation away from core medical technology business
• Dependency on Solana ecosystem's continued growth and adoption

News Market Reaction

-33.61%

34 alerts

-33.61% News Effect

+120.3% Peak Tracked

-15.4% Trough Tracked

-$13M Valuation Impact

$26M Market Cap

0.5x Rel. Volume

On the day this news was published, HSDT declined 33.61%, reflecting a significant negative market reaction. Argus tracked a peak move of +120.3% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $26M at that time.

Data tracked by StockTitan Argus on the day of publication.

NEWTOWN, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana Blockchain. The Company now holds over 760,190 SOL, with an average cost basis of $231. The Company also holds in excess of $335 million of cash, which it intends to use to further the digital asset treasury strategy.

These SOL purchases underscore HSDT’s commitment to the Company’s Solana treasury strategy and long-term confidence in the Solana ecosystem.

“We are excited to embark on our SOL accumulation plan in an efficient manner. The initial accumulation at a lower cost basis than recent market prices, while still retaining the large majority of its capital raised for more opportunistic purchases, showcases how laser focused the team is on maximizing shareholder value by having market awareness and being responsible stewards of capital,” said Cosmo Jiang, Board Observer at HSDT and General Partner at Pantera Capital.

“It has been gratifying to receive shows of support from multiple stakeholders across the Solana ecosystem, including staking providers, DeFi protocols and others. We take our responsibility to maximize shareholder value seriously and are eager to execute against our plan,” said Joseph Chee, Executive Chairman of HSDT.

Solana has historically been the fastest growing blockchain, leading the industry in transaction revenue and processing more than 3,500 transactions per second. The network is also the most widely adopted, averaging about 3.7 million daily active wallets and surpassing 23 billion transactions year to date. SOL is financially productive by design, offering a ~7% native staking yield, whereas assets like BTC are non-yield-bearing. As an independent treasury company, HSDT’s mission is to support the growth and security of tokenized networks by serving as a long-term holder of $SOL, in addition to continuing the development of its neurotech and medical device operations.

Forward Looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. This press release also includes express and implied forward-looking statements regarding the Company's current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as "believes," "expects," "endeavors," "anticipates," "intends," "plans," "estimates," "projects," "should" and "objective" and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that we will achieve or are likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including the risk that we may fail to realize the anticipated benefits of the private placement, including the ability of the Company to execute on its digital asset treasury strategy, as well as risks related to economic conditions, fluctuations in the market price of SOL, and the evolving regulatory environment, as well as other factors. Forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no duty to update such information except as required under applicable law.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit www.heliusmedical.com.

The Company has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises that produce consistent on-chain yield generation. Helius will provide access to the Solana network.

Media Contact

Helius Medical Technologies, Inc.	Phillip Trip Taylor	investorrelations@heliusmedical.com
Pantera Capital Management LP		ir@panteracapital.com press@panteracapital.com

FAQ

How many SOL tokens did Helius Medical Technologies (NASDAQ:HSDT) purchase in September 2025?

Helius Medical Technologies acquired 760,190 SOL tokens at an average cost basis of $231 per token.

What is HSDT's available cash reserve for future SOL purchases?

HSDT maintains over $335 million in cash reserves which it intends to use to further its digital asset treasury strategy.

What is the current transaction capacity and user base of the Solana network?

Solana processes over 3,500 transactions per second and serves approximately 3.7 million daily active wallets, with more than 23 billion transactions year to date.

What is the staking yield for SOL tokens according to HSDT's announcement?

SOL offers approximately 7% native staking yield, unlike non-yield-bearing assets such as Bitcoin.

Will HSDT continue its medical technology operations alongside its SOL strategy?

Yes, HSDT confirmed it will continue the development of its neurotech and medical device operations while serving as a long-term holder of SOL.